Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | MMP8 | P22894 | 8/20 | 0.44 |
| ▸ | MMP3 | P08254 | 5/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084395 | 1.00 | PTPN1 (0.48) | PTPN1MMP8MMP3NR1H2PDE4B | |
| Hydrochloric Acid SCHEMBL2083230 | 0.99 | PTPN1 (0.47) | PTPN1MMP8MMP3NR1H2PDE4B | |
| Hydrochloric Acid SCHEMBL2083227 | 0.99 | PTPN1 (0.47) | PTPN1MMP8MMP3NR1H2PDE4B | |
| SCHEMBL6397202 | 0.83 | PTPN1 (0.68) | PTPN1MMP8MMP3NR1H2 | |
| SCHEMBL18264880 | 0.83 | PTPN1 (0.68) | PTPN1MMP8MMP3NR1H2 | |
| SCHEMBL2084434 | 0.82 | MMP8 (0.48) | PTPN1MMP8MMP3PDE4BPDE4D | |
| SCHEMBL2084435 | 0.82 | MMP8 (0.48) | PTPN1MMP8MMP3PDE4BPDE4D | |
| SCHEMBL2081497 | 0.79 | PTPN1 (0.42) | PTPN1PDE4BPDE4D | |
| SCHEMBL2081496 | 0.79 | PTPN1 (0.42) | PTPN1PDE4BPDE4D | |
| SCHEMBL2083770 | 0.75 | PDE4B (0.38) | PTPN1PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | PTPN1 153/4885MMP8 90/4885MMP3 589/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | PTPN1 825/4885MMP8 136/4885MMP3 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.